Fairless Hills, PA (AP) — Pfizer reported a 32% plunge in second-quarter profit, mainly due to the global coronavirus pandemic limiting marketing of and new prescriptions for its medicines.
Pfizer had predicted in April that the virus would keep both patients and company sales representatives away from doctors and hospitals. Still, the biggest U.S. drugmaker by revenue posted a solid profit and nudged up parts of its 2020 financial forecast and reaffirmed the rest.
The New York company reported net income of $3.43 billion, or 61 cents per share, down from $5.55 billion, or 89 cents, a year earlier. Revenue fell 11% to $11.8 billion, down from $13.26 billion in 2019’s second quarter.
Adjusted income came to $4.4 billion, or 78 cents per share.
Pfizer raised its 2020 earnings-per-share forecast by 3 cents, to $2.85 to $2.95, and tweaked its full-year sales forecast, to a range of $48.6 billion to $50.6 billion, from its April forecast of $48.5 billion to $50.5 billion.
Before you consider Pfizer, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.
While Pfizer currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
